OP0102 Efficacy and Safety of Xeligekimab in Radiographic Axial Spondyloarthritis: Results from a Phase 3 Trial
1. 系统已在2025-07-03 14:45:23对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
S Zhang, D Xu, X Wang, S Liu, F Yuan, W Gou…
Annals of the Rheumatic …, 2025
Elsevier
Background: Radiographic axial spondyloarthritis (r-axSpA), also known as ankylosing spondylitis (AS), is a chronic inflammatory autoimmune disease. Interleukin-17A (IL-17A), a cytokine, plays a key role in the pathogenesis of AS. Xeligekimab (GR1501), a fully human monoclonal antibody that selectively neutralizes IL-17A, has demonstrated potential efficacy in treating r-axSpA. This study represents the first phase 3 clinical trial evaluating Xeligekimab as a treatment for r-axSpA. Objectives: This phase 3 study aimed to determine …
